Trials / Unknown
UnknownNCT05815290
Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
A Phase II Trial of Cadonilimab in Locally Advanced Stage II/III MSI-H/dMMR Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | Cadonilimab 10mg/kg iv on day 1 for every 21 days with a total of 8 cycles |
Timeline
- Start date
- 2023-03-29
- Primary completion
- 2024-09-30
- Completion
- 2026-03-30
- First posted
- 2023-04-18
- Last updated
- 2023-04-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05815290. Inclusion in this directory is not an endorsement.